Interfering with antiviral pathway may deter Alzheimer’s disease and frontotemporal dementia
Targeting part of an antiviral pathway triggered by the accumulation of a key pathogen shared in Alzheimer’s disease and frontotemporal dementia may one day offer a new therapeutic approach to deterring or delaying cognitive decline, according to preclinical research led by Weill Cornell Medicine scientists.
The study, published April 24 in Nature Neuroscience, demonstrates that inhibiting an innate immune system enzyme called cyclic GMP–AMP synthase (cGAS) helps neurons become resilient to the build-up of the protein tau into bundles known as fibrils, a hallmark of Alzheimer’s and some forms of frontotemporal dementia, the two most ...













